Surgical Valve Repair and Replacement Reimbursement Analysis

Medicare has historically been the most common payer among surgical valve repair and replacement procedures; however, payer mix for surgical procedures may shift in the future as transcatheter valve treatment options continue to evolve.

Guideline recommendations support the use of tissue valves in some patients younger than 65 years.[1] Therefore, a better understanding of the commercial reimbursement landscape for valve repair and replacement procedures is warranted.

The objective of this analysis was to understand the difference in payment between Commercial, Medicare and Medicaid patients undergoing surgical heart valve repair and replacement procedures.

Payer Mix[2]



Payment Range for Valve Procedures[3]

Commercial Reimbursement	**$99,881 - $107,642**
Medicare Reimbursement	**$55,026 - $61,866**

Conclusions

Commercial payments are higher than Medicare payments for surgical valve procedures.

+87% for SAVR

+75% for SMVr

+74% for SMVR

Commercial, Medicare and Medicaid Payments for Surgical Heart Valve Procedures

DRGs (216-221) Oct 20 to Sep 21



*Compared to Medicare

Edwards

Open Surgical Aortic Valve Replacement (SAVR)

02RF07Z	Replacement of Aortic Valve with Autologous Tissue Substitute, Open Approach
02RF08Z	Replacement of Aortic Valve with Zooplastic Tissue, Open Approach
02RF0KZ	Replacement of Aortic Valve with Nonautologous Tissue Substitute, Open Approach
02RF47Z	Replacement of Aortic Valve with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
02RF48Z	Replacement of Aortic Valve with Zooplastic Tissue, Pecrutaneous Endoscopic Approach
02RF4KZ	Replacement of Aortic Valve with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
02RF0JZ	Replacement of Aortic Valve with Synthetic Substitute, Open Approach
02RF4JZ	Replacement of Aortic Valve with Synthetic Substitute, Percutaneous Endoscopic Approach

Open Surgical Mitral Valve Replacement (SMVR)

02RG07Z	Replacement of Mitral Valve with Autologous Tissue Substitute, Open Approach
02RG08Z	Replacement of Mitral Valve with Zooplastic Tissue, Open Approach
02RG0JZ	Replacement of Mitral Valve with Synthetic Substitute, Open Approach
02RG0KZ	Replacement of Mitral Valve with Non-Autologous Tissue Substitute, Open Approach

Open Surgical Mitral Valve Repair (SMVr)

02UG0JZ	Supplement Mitral Valve with Synthetic Substitute, Open Approach
02QG0ZZ	Repair Mitral Valve, Open Approach
02UG08Z	Supplement Mitral Valve with Zooplastic Tissue, Open Approach
02UG07Z	Supplement Mitral Valve with Autologous Tissue Substitute, Open Approach
02QG0ZE	Repair Mitral Valve created from Left Atrioventricular Valve, Open Approach
02UG0KZ	Supplement Mitral Valve with Nonautologous Tissue Substitute, Open Approach
02UG0JE	Supplement Mitral Valve created from Left Atrioventricular Valve with Synthetic Substitute, Open Approach
02WG08Z	Revision of Zooplastic Tissue in Mitral Valve, Open Approach
02WG0JZ	Revision of Synthetic Substitute in Mitral Valve, Open Approach
02UG07E	Supplement Mitral Valve created from Left Atrioventricular Valve with Autologous Tissue Substitute, Open Approach
02UG08E	Supplement Mitral Valve created from Left Atrioventricular Valve with Zooplastic Tissue, Open Approach
02WG0KZ	Revision of Nonautologous Tissue Substitute in Mitral Valve, Open Approach
02UG0KE	Supplement Mitral Valve created from Left Atrioventricular Valve with Nonautologous Tissue Substitute, Open Approach
02WG07Z	Revision of Autologous Tissue Substitute in Mitral Valve, Open Approach

Important - Please Note:
This information is provided as a general educational resource and is not intended to constitute medical advice or in any way replace the independent medical judgment of a trained and licensed physician with respect to any individual patient needs or circumstances. Coverage, reimbursement and health economics information provided by Edwards is gathered from third-party sources and presented for illustrative purposes only. This information does not constitute reimbursement or legal advice, and Edwards makes no representation or warranty regarding this information or its completeness, accuracy, or timeliness. Laws, regulations, and payer policies concerning reimbursement are complex and change frequently; service providers are responsible for all decisions relating to coding and reimbursement submissions.

As a member of the Advanced Medical Technology Association ("AdvaMed"), Edwards strictly adheres to the requirements of the AdvaMed Code of Ethics on Interactions with Health Care Professionals. If required by law (e.g., US Sunshine Law), Edwards will disclose the value of this educational item, and Edwards also may publish such information on its website or other public manner in order to provide the public with full disclosure of its financial arrangements with health care professionals.

References:
1. Otto CM, Nishimura RA, Bonow RA, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circ 2021;143(5):e72-e227.
2. Agency for Healthcare Research and Quality (AHRQ). Healthcare Cost and Utilization Project (HCUP) 2019 National Statistics, Payer-mix data.
3. Commercial, Medicare and Mediccaid data : National Inpatient hospital dataset of all-payor data from 241 facilities. (October 2020 to September 2021)

Edwards Lifesciences • One Edwards Way, Irvine CA 92614 USA • edwards.com

Edwards